PHILADELPHIA — More adults with IgE-mediated peanut allergy receiving remibrutinib vs. placebo for 4 weeks tolerated a single dose of at least 600 mg peanut protein without dose-limiting symptoms, according to a presentation here.
These data on remibrutinib, a novel, highly selective, oral Bruton’s tyrosine kinase inhibitor, were presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
“Remibrutinib showed superior efficacy vs. placebo with dose-dependent effects,” Robert A. Wood, MD, FAAAAI, professor of pediatrics at Johns Hopkins University School of Medicine and

To inform clinicians on the best biologic agent for different populations of adults with severe asthma, 12 experts collaborated on a new clinical practice guideline published in CHEST, according to a press release.
After developing seven questions using the population, intervention, comparator and outcome (PICO) format and conducting a systematic review of 44 studies related to the topic, the panel established seven evidence-based recommendations.
The recommendations discuss which biologic to consider for adults with severe asthma with moderate to severe allergic asthma and a history of at

Colorectal cancer is now the leading cause of cancer deaths among individuals aged younger than 50 years, and incidence continues to rise.
However, the disease is also one of the most preventable and easiest to treat if caught early.
“Clinicians and patients don’t fully appreciate that this is a cancer that is completely preventable by finding polyps,” Neil D. Parikh, MD, told Healio. “That message really needs to be stressed.”
“We need to shift the narrative from ‘do I have cancer?’ to ‘let’s stop cancer before it starts,’” Parikh, chief of gastroenterology at Hartford Hospitals, chief

Hot dogs at the ballpark on Friday night. Bacon and eggs for Sunday breakfast. A deli sandwich for a grab-and-go weekday lunch.
All are staples of the typical American’s diet.
However, a new poll suggests nearly half of U.S. adults are unaware that eating these foods and other processed meats increases their risk for colorectal cancer.
The results are disappointing but not surprising, according to Anna Herby, DHSc, RD, CDCES, a nutrition education specialist with Physicians Committee for Responsible Medicine (PCRM), told Healio.
“We certainly wish more people knew about the link,” Herby told

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl peptidase 4 inhibitors, according to data.
Meanwhile, neither glucagon-like peptide-1 (GLP-1) receptor agonists nor SGLT2 inhibitors bested DPP4 inhibitors for reducing other autoimmune rheumatic diseases, in the same patient population, over an average period of 1 to 2 years.
“Overall, we found that taking GLP-1 receptor agonists and SGLT2 inhibitors for around 1 to 2 years did not